Advanced

Inhaled Corticosteroid/Long-Acting beta(2)-Agonist Combination Therapy for Asthma: Attitudes of Specialists in Europe

Bousquet, Jean; Winchester, Chris; Papi, Alberto; Virchow, J. Christian; Haughney, John; Costa, David; Usmani, Omar; Bjermer, Leif LU and Price, David (2012) In International Archives of Allergy and Immunology 157(3). p.303-310
Abstract
Background: As new combinations of inhaled corticosteroids (ICSs) and long-acting beta(2)-agonists (LABAs) become available for the treatment of asthma, it will be important to determine criteria against which they can be evaluated. The aim of this study was to assess which attributes of combination therapy physicians consider most important. Methods: Primary and secondary care asthma specialists (n = 32) were recruited for an expert Delphi process that was performed over three rounds to determine attributes perceived to be important in the selection of combination therapy. A pan-European survey was carried out to assess the attitudes, perceptions and prescribing behaviour of a larger population (n = 1,861) of physicians with a specialist... (More)
Background: As new combinations of inhaled corticosteroids (ICSs) and long-acting beta(2)-agonists (LABAs) become available for the treatment of asthma, it will be important to determine criteria against which they can be evaluated. The aim of this study was to assess which attributes of combination therapy physicians consider most important. Methods: Primary and secondary care asthma specialists (n = 32) were recruited for an expert Delphi process that was performed over three rounds to determine attributes perceived to be important in the selection of combination therapy. A pan-European survey was carried out to assess the attitudes, perceptions and prescribing behaviour of a larger population (n = 1,861) of physicians with a specialist interest in asthma treatment. Results: The expert Delphi panel (response rate 59.4%) agreed that the availability of a range of doses (88% agreement in the final round), the efficacy of the combination (81%) and the safety and tolerability of the therapy (81%) were important attributes of ICS/LABA combination treatment. The potency of the ICS (69%) and the speed of onset of the LABA (69%) were also prioritized. The results of the attitudinal survey (eligibility rate 54.1%) showed that the same factors were considered important in everyday clinical practice. Conclusions: These studies identified which attributes of an ICS/LABA treatment are considered most important by an expert panel and a broader group of physicians; further research is warranted to better understand the influences that drive physician opinions. Copyright (C) 2011 S. Karger AG, Basel (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Asthma, Delphi process, Inhaled corticosteroid, Long-acting, beta(2)-agonist
in
International Archives of Allergy and Immunology
volume
157
issue
3
pages
303 - 310
publisher
Karger
external identifiers
  • wos:000300405800013
  • scopus:80155182205
ISSN
1423-0097
DOI
10.1159/000329519
language
English
LU publication?
yes
id
d9d17afe-493f-47ec-a3c3-2a5712b5fb65 (old id 2409672)
date added to LUP
2012-04-02 09:31:31
date last changed
2017-01-01 03:41:10
@article{d9d17afe-493f-47ec-a3c3-2a5712b5fb65,
  abstract     = {Background: As new combinations of inhaled corticosteroids (ICSs) and long-acting beta(2)-agonists (LABAs) become available for the treatment of asthma, it will be important to determine criteria against which they can be evaluated. The aim of this study was to assess which attributes of combination therapy physicians consider most important. Methods: Primary and secondary care asthma specialists (n = 32) were recruited for an expert Delphi process that was performed over three rounds to determine attributes perceived to be important in the selection of combination therapy. A pan-European survey was carried out to assess the attitudes, perceptions and prescribing behaviour of a larger population (n = 1,861) of physicians with a specialist interest in asthma treatment. Results: The expert Delphi panel (response rate 59.4%) agreed that the availability of a range of doses (88% agreement in the final round), the efficacy of the combination (81%) and the safety and tolerability of the therapy (81%) were important attributes of ICS/LABA combination treatment. The potency of the ICS (69%) and the speed of onset of the LABA (69%) were also prioritized. The results of the attitudinal survey (eligibility rate 54.1%) showed that the same factors were considered important in everyday clinical practice. Conclusions: These studies identified which attributes of an ICS/LABA treatment are considered most important by an expert panel and a broader group of physicians; further research is warranted to better understand the influences that drive physician opinions. Copyright (C) 2011 S. Karger AG, Basel},
  author       = {Bousquet, Jean and Winchester, Chris and Papi, Alberto and Virchow, J. Christian and Haughney, John and Costa, David and Usmani, Omar and Bjermer, Leif and Price, David},
  issn         = {1423-0097},
  keyword      = {Asthma,Delphi process,Inhaled corticosteroid,Long-acting,beta(2)-agonist},
  language     = {eng},
  number       = {3},
  pages        = {303--310},
  publisher    = {Karger},
  series       = {International Archives of Allergy and Immunology},
  title        = {Inhaled Corticosteroid/Long-Acting beta(2)-Agonist Combination Therapy for Asthma: Attitudes of Specialists in Europe},
  url          = {http://dx.doi.org/10.1159/000329519},
  volume       = {157},
  year         = {2012},
}